 FOSTER CITY, Calif., Sept. 02, 2021 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis NASH and other chronic liver diseases, today announced that the Companys management team will present at the following upcoming investor conferences in September: 